Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level650 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03704077 | An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 14 | May 19, 2020 | clinicaltrials |
| NCT01913639 | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | completed | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 |
| May 15, 2020 |
| clinicaltrials |
| NCT04367025 | Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer | unknown | Phase 2 | 70 | Chinese PLA General HospitalOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT04152889 | A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT04345770 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer | unknown | Phase 2 | 100 | Wuhan UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT04345783 | Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer | unknown | Phase 2 | 30 | Beijing Friendship HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02528110 | Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer | completed | Phase 2 | 100 | Wuhan UniversityOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT03606928 | mFLOT Chemotherapy as First-line Treatment in GC | completed | Phase 1 / Phase 2 | 18 | Ruijin HospitalOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04286711 | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 52 | China Medical University, ChinaOTHER | 1 | Feb 27, 2020 | clinicaltrials |
| NCT00439608 | Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer | completed | Phase 2 | 60 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 34 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01516944 | Perioperative Chemotherapy for Potentially Resectable Gastric Cancer | completed | Phase 2 / Phase 3 | 749 | Hebei Medical UniversityOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04263870 | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(CTSCAPOXSEA) | unknown | Phase 2 | 36 | Sichuan UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT00525785 | Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | completed | Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01747551 | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | completed | Phase 2 | 64 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04065282 | The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma. | unknown | Phase 2 | 36 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT04258644 | Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer | unknown | Phase 2 | 30 | Beijing Friendship HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT04258657 | Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer | unknown | Phase 2 | 20 | Beijing Friendship HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT03192735 | Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer | unknown | Phase 2 | 50 | Chang-Ming Huang, Prof.OTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03957564 | Liquid Biopsy in Monitoring the Neoadjuvant Chemotherapy and Operation in Gastric Cancer | unknown | Phase 2 | 40 | Affiliated Hospital of Qinghai UniversityOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02726399 | Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer | terminated | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT00565370 | Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP | completed | Phase 1 / Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00398398 | Study of XELOX With Cetuximab in Advanced Gastric Cancer | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT00976768 | Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01045538 | Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP | completed | Phase 1 / Phase 2 | 45 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01187212 | Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE | completed | Phase 2 | 195 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01471470 | Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer | completed | Phase 2 | 31 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01719549 | Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1 | completed | Phase 2 | 19 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT02451956 | Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy | completed | Phase 2 | 21 | Samsung Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04202484 | Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Gastric and Gastroesophageal Junction Adenocarcinoma | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT00515411 | Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 111 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | unknown | Phase 2 | 116 | Zhejiang Cancer HospitalOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04182724 | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 57 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04005365 | Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer | unknown | Phase 2 | 78 | Yijing HeOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02204306 | Genotype Guided Chemotherapy in Gastric Cancer Patients | completed | Phase 2 | 330 | Central South UniversityOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02585908 | Safety and Efficacy of γδ T Cell Against Gastric Cancer | unknown | Phase 1 / Phase 2 | 120 | Beijing Doing Biomedical Co., Ltd.INDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01498289 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | completed | Phase 2 | 213 | SWOG Cancer Research NetworkNETWORK | 1 | Nov 7, 2019 | clinicaltrials |
| NCT04155671 | POF Versus FOLFOX Plus IP Paclitaxel in AGC | unknown | Phase 2 | 260 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 7, 2019 | clinicaltrials |
| NCT04149015 | Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 4, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | unknown | Phase 2 | 116 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 9, 2019 | clinicaltrials |
| NCT01983878 | A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 30, 2019 | clinicaltrials |
| NCT03766607 | Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer | withdrawn | Phase 2 | 0 | Korean South West Oncology GroupNETWORK | 1 | Sep 19, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT04089657 | Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens(ASGARD) | unknown | Phase 2 | 40 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 13, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 19, 2020source: clinicaltrials